Insulin drug
Pro Research Analysisby 
Searched over 200M research papers for "insulin drug"
Advances in Insulin Drug Therapies for Diabetes
Introduction to Insulin Drug Therapies
Insulin remains a cornerstone in the management of diabetes, particularly for patients with type 1 diabetes (T1D) and advanced type 2 diabetes (T2D). Over the years, significant advancements have been made in the development of insulin formulations and delivery methods, aiming to improve efficacy, safety, and patient convenience.
Oral Insulin: A New Frontier
Efficacy and Safety of Oral Basal Insulin
Recent studies have explored the potential of oral insulin formulations. One such study compared the efficacy and safety of oral insulin 338 (I338) with subcutaneous insulin glargine (IGlar) in patients with T2D. The findings indicated that I338 could safely improve glycemic control with no significant difference in fasting plasma glucose (FPG) levels compared to IGlar. However, the high doses required for I338 made its production commercially unviable, leading to the discontinuation of its development .
Biosimilar Insulins: Improving Access
Bioequivalence of Regular Human Insulins
Biosimilar insulins have emerged as a promising alternative to branded insulins, potentially improving access to insulin therapy. A study comparing the pharmacokinetic and pharmacodynamic profiles of a biosimilar insulin produced by Bioton S.A. and Humulin® R demonstrated bioequivalence, suggesting that biosimilar insulins could be a viable option for patients with T1D .
Innovations in Insulin Delivery
Continuous Subcutaneous Insulin Infusion (CSII)
Continuous subcutaneous insulin infusion (CSII) combined with oral glucose-lowering drugs (GLDs) has shown significant clinical efficacy in managing T2D. A network meta-analysis revealed that CSII combined with metformin was particularly effective in controlling fasting blood glucose and improving insulin resistance. Additionally, combining CSII with a DPP-4 inhibitor was the most effective in reducing glycosylated hemoglobin levels .
Inhaled and Ultrafast Insulins
The development of inhaled insulin and ultrafast-acting insulin analogs has provided new options for insulin delivery. These innovations aim to mimic physiological insulin secretion more closely and offer greater convenience for patients. Inhaled insulin, in particular, has shown promise as an alternative to injectable insulin, potentially improving patient adherence Nally2019Cahn2015.
Adjunctive Therapies in Insulin Treatment
Combining Insulin with GLDs
Combining insulin therapy with newer glucose-lowering drugs, such as GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors, has shown to enhance glycemic control while reducing insulin doses, weight gain, and hypoglycemic episodes. These combination therapies offer a more individualized approach to diabetes management, addressing the diverse needs of patients Cahn2015Aschner2020.
Dulaglutide vs. Insulin Glargine
In patients with T2D and chronic kidney disease, dulaglutide, a GLP-1 receptor agonist, has been compared with insulin glargine. The study found that dulaglutide provided similar glycemic control with a reduced decline in estimated glomerular filtration rate (eGFR) and a lower risk of hypoglycemia, making it a safer option for patients with kidney disease .
Conclusion
The landscape of insulin therapy for diabetes is rapidly evolving, with new formulations and delivery methods enhancing the efficacy, safety, and convenience of treatment. Oral insulin, biosimilar insulins, and innovative delivery methods like CSII and inhaled insulin are expanding the options available to patients. Additionally, combining insulin with newer glucose-lowering drugs offers a more tailored approach to diabetes management, potentially improving outcomes and quality of life for patients. As research continues, these advancements hold promise for more effective and patient-friendly diabetes care.
Sources and full results
Most relevant research papers on this topic